Cargando…

Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients

Background: An analysis of red blood cell alloimmunization in patients with thalassemia can help to devise specific strategies to decrease the alloimmunization rate. This study explored the frequency and specificity of alloantibodies and autoantibodies against red blood cell (RBC) antigens in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaiegan, Mojgan, Moghaddam, Mostafa, Maghsudlu, Mahtab, Azarkeivan, Azita, Zolfaghari, Sima, Pourfatollah, Ali-Akbar, Soleimanzadeh, Peyman, Shahverdi, Ehsan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339119/
https://www.ncbi.nlm.nih.gov/pubmed/35975116
http://dx.doi.org/10.18502/ijhoscr.v16i1.8435
_version_ 1784760122272120832
author Shaiegan, Mojgan
Moghaddam, Mostafa
Maghsudlu, Mahtab
Azarkeivan, Azita
Zolfaghari, Sima
Pourfatollah, Ali-Akbar
Soleimanzadeh, Peyman
Shahverdi, Ehsan
author_facet Shaiegan, Mojgan
Moghaddam, Mostafa
Maghsudlu, Mahtab
Azarkeivan, Azita
Zolfaghari, Sima
Pourfatollah, Ali-Akbar
Soleimanzadeh, Peyman
Shahverdi, Ehsan
author_sort Shaiegan, Mojgan
collection PubMed
description Background: An analysis of red blood cell alloimmunization in patients with thalassemia can help to devise specific strategies to decrease the alloimmunization rate. This study explored the frequency and specificity of alloantibodies and autoantibodies against red blood cell (RBC) antigens in patients with thalassemia referring to the Iranian Blood Transfusion Organization (IBTO) Immunohematology Reference Laboratory (IRL) in Tehran. Materials and Methods: This study first examined the laboratory records of 23,113 patients suffering from different diseases referring to IBTO’s IRL for pretransfusion testing in the 2008-2015 period. ABO and Rh(D) typing and antibody screening tests were performed for all 23,113 patient records and 685 (2.97%) beta-thalassemia patients with positive pre-transfusion test results (antibody screening and/or DAT) were selected for further investigation. Results: The antibody screening test was positive in 640 out of 685 thalassemic patients (93.4%). DAT was performed for 529 patients, 226 (33%) of which showed positive results. Meanwhile, 161 out of 685 beta-thalassemia patients (23.5%) had positive auto control test results, reflecting the possible presence of allo- and/or autoantibodies. The most common antigen-specific alloantibodies were directed against K and E RBC antigens with a frequency of 25% (Anti-K) and 11.91% (Anti-E), respectively. The development of two antibodies (double antibodies) in one patient was observed in 80 individuals (11.46%). Conclusion: Age, gender, history of pregnancy, and splenectomy were not contributing factors to the antibody presence in the patient population under study. Extended red blood cell phenotyping should be considered as an essential procedure for expected multi-transfused thalassemia patients before blood transfusion. Considering the high frequency of anti-K and anti-E observed in this study, it is recommended that thalassemia patients in Iran are tested through phenotyping of RBC units for K and E antigens before transfusion.
format Online
Article
Text
id pubmed-9339119
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center
record_format MEDLINE/PubMed
spelling pubmed-93391192022-08-15 Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients Shaiegan, Mojgan Moghaddam, Mostafa Maghsudlu, Mahtab Azarkeivan, Azita Zolfaghari, Sima Pourfatollah, Ali-Akbar Soleimanzadeh, Peyman Shahverdi, Ehsan Int J Hematol Oncol Stem Cell Res Original Article Background: An analysis of red blood cell alloimmunization in patients with thalassemia can help to devise specific strategies to decrease the alloimmunization rate. This study explored the frequency and specificity of alloantibodies and autoantibodies against red blood cell (RBC) antigens in patients with thalassemia referring to the Iranian Blood Transfusion Organization (IBTO) Immunohematology Reference Laboratory (IRL) in Tehran. Materials and Methods: This study first examined the laboratory records of 23,113 patients suffering from different diseases referring to IBTO’s IRL for pretransfusion testing in the 2008-2015 period. ABO and Rh(D) typing and antibody screening tests were performed for all 23,113 patient records and 685 (2.97%) beta-thalassemia patients with positive pre-transfusion test results (antibody screening and/or DAT) were selected for further investigation. Results: The antibody screening test was positive in 640 out of 685 thalassemic patients (93.4%). DAT was performed for 529 patients, 226 (33%) of which showed positive results. Meanwhile, 161 out of 685 beta-thalassemia patients (23.5%) had positive auto control test results, reflecting the possible presence of allo- and/or autoantibodies. The most common antigen-specific alloantibodies were directed against K and E RBC antigens with a frequency of 25% (Anti-K) and 11.91% (Anti-E), respectively. The development of two antibodies (double antibodies) in one patient was observed in 80 individuals (11.46%). Conclusion: Age, gender, history of pregnancy, and splenectomy were not contributing factors to the antibody presence in the patient population under study. Extended red blood cell phenotyping should be considered as an essential procedure for expected multi-transfused thalassemia patients before blood transfusion. Considering the high frequency of anti-K and anti-E observed in this study, it is recommended that thalassemia patients in Iran are tested through phenotyping of RBC units for K and E antigens before transfusion. Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2022-01-01 /pmc/articles/PMC9339119/ /pubmed/35975116 http://dx.doi.org/10.18502/ijhoscr.v16i1.8435 Text en Copyright © 2022 Tehran University of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
spellingShingle Original Article
Shaiegan, Mojgan
Moghaddam, Mostafa
Maghsudlu, Mahtab
Azarkeivan, Azita
Zolfaghari, Sima
Pourfatollah, Ali-Akbar
Soleimanzadeh, Peyman
Shahverdi, Ehsan
Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients
title Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients
title_full Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients
title_fullStr Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients
title_full_unstemmed Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients
title_short Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients
title_sort red blood cell immunization and contributing factors in 685 thalassemia patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339119/
https://www.ncbi.nlm.nih.gov/pubmed/35975116
http://dx.doi.org/10.18502/ijhoscr.v16i1.8435
work_keys_str_mv AT shaieganmojgan redbloodcellimmunizationandcontributingfactorsin685thalassemiapatients
AT moghaddammostafa redbloodcellimmunizationandcontributingfactorsin685thalassemiapatients
AT maghsudlumahtab redbloodcellimmunizationandcontributingfactorsin685thalassemiapatients
AT azarkeivanazita redbloodcellimmunizationandcontributingfactorsin685thalassemiapatients
AT zolfagharisima redbloodcellimmunizationandcontributingfactorsin685thalassemiapatients
AT pourfatollahaliakbar redbloodcellimmunizationandcontributingfactorsin685thalassemiapatients
AT soleimanzadehpeyman redbloodcellimmunizationandcontributingfactorsin685thalassemiapatients
AT shahverdiehsan redbloodcellimmunizationandcontributingfactorsin685thalassemiapatients